肝细胞癌的靶向治疗

Targeted therapy for hepatocellular carcinoma

近年来,随着肝细胞癌(HCC)分子机制研究深入,靶向治疗也得到了迅猛发展,在延缓和改善患者疾病进展和预后方面作出了巨大贡献。由于HCC的发病机制错综复杂,单一的分子靶向治疗总体临床收益并不理想。因此,近年来靶向联合其他治疗方式的新方案不断出新,并取得了令人鼓舞的成果。就HCC分子靶向治疗药物、研究现状及临床联合应用治疗进展予以简要总结。

With the in-depth research on the molecular mechanism of hepatocellular carcinoma(HCC)in recent years,targeted therapy has achieved rapid development and made great contributions to delaying disease progression and improving prognosis.Due to the complex pathogenesis of HCC,molecular targeted therapy alone has unsatisfactory overall clinical benefits;therefore,new treatment regimens of targeted therapy in combination with other treatment modalities continue to appear in recent years and have obtained encouraging results.This article briefly summarizes the drugs used in molecular targeted therapy,the current research status of molecular targeted therapy,and the advances in its combination with other treatment modalities for HCC.